Testing effectiveness (Phase 2)UnknownNCT04339829
What this trial is testing
An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
Who this might be right for
Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
Guangdong Association of Clinical Trials 50